NO910811L - Vevsplasminogen-aktivator med zymogeniske- eller fibrinspesifikke egenskaper. - Google Patents

Vevsplasminogen-aktivator med zymogeniske- eller fibrinspesifikke egenskaper.

Info

Publication number
NO910811L
NO910811L NO91910811A NO910811A NO910811L NO 910811 L NO910811 L NO 910811L NO 91910811 A NO91910811 A NO 91910811A NO 910811 A NO910811 A NO 910811A NO 910811 L NO910811 L NO 910811L
Authority
NO
Norway
Prior art keywords
zymogens
variants
zymogenic
plasminogen activator
tissue plasminogen
Prior art date
Application number
NO91910811A
Other languages
English (en)
Other versions
NO310778B1 (no
NO910811D0 (no
Inventor
Stephen Anderson
William F Bennett
David Botstein
Deborah L Higgins
Nicholas F Paoni
Mark Zoller
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO910811D0 publication Critical patent/NO910811D0/no
Publication of NO910811L publication Critical patent/NO910811L/no
Publication of NO310778B1 publication Critical patent/NO310778B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
NO19910811A 1988-09-02 1991-02-28 Fremgangsmåte for fremstilling av vevsplasminogen-aktivator med zymogeniske eller fibrinspesifikke egenskaper NO310778B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24085688A 1988-09-02 1988-09-02
US07/384,608 US5108901A (en) 1988-09-02 1989-07-24 Tissue plasminogen activator having zymogenic or fibrin specific properties
PCT/US1989/003755 WO1990002798A1 (en) 1988-09-02 1989-08-29 Tissue plasminogen activator having zymogenic or fibrin specific properties

Publications (3)

Publication Number Publication Date
NO910811D0 NO910811D0 (no) 1991-02-28
NO910811L true NO910811L (no) 1991-02-28
NO310778B1 NO310778B1 (no) 2001-08-27

Family

ID=26933781

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19910811A NO310778B1 (no) 1988-09-02 1991-02-28 Fremgangsmåte for fremstilling av vevsplasminogen-aktivator med zymogeniske eller fibrinspesifikke egenskaper

Country Status (18)

Country Link
US (1) US5108901A (no)
EP (1) EP0457758B1 (no)
JP (1) JP2794028B2 (no)
KR (1) KR0148575B1 (no)
AT (1) ATE124452T1 (no)
AU (1) AU626323B2 (no)
CA (1) CA1341484C (no)
DE (1) DE68923298T2 (no)
DK (1) DK175958B1 (no)
ES (1) ES2018729A6 (no)
FI (1) FI109359B (no)
HK (1) HK1007334A1 (no)
HU (1) HU213922B (no)
IE (1) IE67508B1 (no)
IL (1) IL91306A (no)
NO (1) NO310778B1 (no)
NZ (1) NZ230509A (no)
WO (1) WO1990002798A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756093A (en) * 1985-04-22 1998-05-26 Genentech, Inc. Tissue plasminogen activator variants
US5736134A (en) * 1985-04-22 1998-04-07 Genentech, In.C Tissue plasminogen activator variants
GB8815135D0 (en) * 1988-06-24 1988-08-03 British Bio Technology Proteins & nucleic acids
DK395288D0 (da) * 1988-07-15 1988-07-15 Novo Industri As Proteiner
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5156969A (en) * 1988-09-02 1992-10-20 Genentech Inc. Tissue plasminogen activator variant with deletion of amino acids 466-470 having fibrin specific properties
US5866413A (en) * 1989-03-06 1999-02-02 Board Of Regents Of The University Of Texas System Pai-1 mutants
DE69034013T2 (de) * 1989-03-06 2003-07-31 Univ Texas Serpin-resistenter T-PA; Mutanten; Gene
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
US5550042A (en) * 1989-03-06 1996-08-27 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors and genes encoding the same and serine protease inhibitor mutants and genes encoding the same
AU664469B2 (en) * 1992-06-03 1995-11-16 Genentech Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
US5472692A (en) * 1993-07-02 1995-12-05 New England Deaconess Hospital Corporation Pro-urokinase mutants
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5656427A (en) * 1994-08-29 1997-08-12 Gen-Probe Incorporated Nucleic acid hybridization assay probes, helper probes and amplification oligonucleotides targeted to Mycoplasma pneumoniae nucleic acid
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
US6610296B2 (en) 1995-10-26 2003-08-26 Genentech, Inc. Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
US6706504B1 (en) 1996-11-12 2004-03-16 The Scripps Research Institute Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
CA2271697C (en) * 1996-11-12 2007-10-23 The Scripps Research Institute Tissue type plasminogen activator (t-pa) variants: compositions and methods of use
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
DE69737457T2 (de) 1997-01-31 2007-11-29 Genentech, Inc., South San Francisco O-fukosyltransferase
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
AU8864398A (en) * 1997-08-13 1999-03-08 Boehringer Mannheim Gmbh Plasminogen activator with enhanced zymogenic power and reduced fibrin linking
AU9162198A (en) * 1997-08-13 1999-03-08 Boehringer Mannheim Gmbh Plasminogen activator with improved zymogenity
KR100408844B1 (ko) * 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
US8969295B2 (en) * 2006-04-14 2015-03-03 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
JP2009544325A (ja) * 2006-07-27 2009-12-17 セントカー・インコーポレーテツド Ｂｍｐ−７変異体組成物、方法および使用
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
EA035358B1 (ru) 2014-11-03 2020-06-01 ТРОМБОЛИТИК САЙЕНС, ЭлЭлСи Способ, набор и комбинация для лечения субъекта с симптомами инсульта или острого инфаркта миокарда
US11154596B2 (en) 2017-06-16 2021-10-26 Thrombolytic Science, Llc Methods for thrombolysis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125269A1 (en) * 1982-11-11 1984-11-21 Beecham Group Plc Pharmaceutically active compounds
DE3382389D1 (de) * 1982-12-14 1991-10-02 South African Inventions Plasminogenaktivator.
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
DE3682104D1 (de) * 1985-04-22 1991-11-28 Genentech Inc Plasminogenaktivator-mutante des menschlichen gewebes, verfahren und zwischenprodukte dafuer und diese mutante verwendende zusammensetzungen.
GB8528321D0 (en) * 1985-11-18 1985-12-24 Ciba Geigy Ag Modified fibrinolytic agents
DE3684680D1 (de) * 1985-12-23 1992-05-07 Chiron Corp Peptidplasminogenaktivatoren.
DK43387A (da) * 1986-01-29 1987-07-30 Beecham Group Plc Fibrinolytisk enzym
AU612974B2 (en) * 1986-01-31 1991-07-25 Genetics Institute, Llc Novel thrombolytic proteins
IE81073B1 (en) * 1986-03-18 2000-01-12 Genentech Inc Modified human tissue-type plasminogen activator and its preparation
PT84589B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
DK345087A (da) * 1986-07-11 1988-01-12 Novo Industri As Modificeret vaevsplasminogenaktivator
WO1988005081A2 (en) * 1986-12-30 1988-07-14 Cetus Corporation Novel plasminogen activator
GB8705377D0 (en) * 1987-03-07 1987-04-08 Beecham Group Plc Compounds
EP0292009A1 (en) * 1987-05-22 1988-11-23 Zymogenetics, Inc. Fibrinolytic proteins
DE3851259T2 (de) * 1987-06-04 1994-12-15 Zymogenetics Inc Mutierter t-PA mit Kringle-Ersatz.
IE67036B1 (en) * 1987-06-04 1996-05-15 Zymogenetics Inc Tissue plasminogen activator analogs having modified growth factor domains
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
WO1988010119A1 (en) * 1987-06-22 1988-12-29 Genetics Institute, Inc. Novel thrombolytic proteins
WO1989000191A1 (en) * 1987-07-06 1989-01-12 Genetics Institute, Inc. Novel thrombolytic proteins
AU1893988A (en) * 1987-07-13 1989-01-19 Collaborative Research Inc. Nonglycosylated plasminogen activator and method of preparation
DK395288D0 (da) * 1988-07-15 1988-07-15 Novo Industri As Proteiner

Also Published As

Publication number Publication date
HU896005D0 (en) 1991-07-29
AU4194689A (en) 1990-04-02
AU626323B2 (en) 1992-07-30
IL91306A (en) 1997-08-14
NO310778B1 (no) 2001-08-27
FI911049A0 (fi) 1991-03-01
DK36991D0 (da) 1991-03-01
IL91306A0 (en) 1990-03-19
US5108901A (en) 1992-04-28
IE892650L (en) 1990-03-02
DK36991A (da) 1991-05-02
HK1007334A1 (en) 1999-04-09
DK175958B1 (da) 2005-08-29
CA1341484C (en) 2005-05-24
ES2018729A6 (es) 1991-05-01
ATE124452T1 (de) 1995-07-15
JP2794028B2 (ja) 1998-09-03
DE68923298T2 (de) 1996-01-11
NO910811D0 (no) 1991-02-28
FI109359B (fi) 2002-07-15
EP0457758B1 (en) 1995-06-28
EP0457758A1 (en) 1991-11-27
IE67508B1 (en) 1996-04-03
WO1990002798A1 (en) 1990-03-22
DE68923298D1 (de) 1995-08-03
JPH04500157A (ja) 1992-01-16
NZ230509A (en) 1991-06-25
HUT58812A (en) 1992-03-30
KR0148575B1 (ko) 1998-10-15
HU213922B (en) 1997-11-28
KR900702019A (ko) 1990-12-05

Similar Documents

Publication Publication Date Title
NO910811D0 (no) Vevsplasminogen-aktivator med zymogeniske- eller fibrinspesifikke egenskaper.
Serrano The long road of research on snake venom serine proteinases
Toombs Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis
Matsuda et al. A simple, large scale method for preparation of plasminogen-free fibrinogen
Girón et al. Isolation and characterization of two new non-hemorrhagic metalloproteinases with fibrinogenolytic activity from the mapanare (Bothrops colombiensis) venom
Silverstein et al. Thrombospondin-plasminogen interactions: modulation of plasmin generation
DK0517756T3 (da) Vævs-plasminogenaktivator med fibrinspecifikke egenskaber
Paoni et al. Involvement of residues 296–299 in the enzymatic activity of tissue-type plasminogen activator
Bachmann Fibrinolytic agents
Gardell The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk
Deguchi et al. Plasminogen activation by tissue plasminogen activator in the presence of platelets
DK0542869T3 (da) Vævsplasminogenaktivatorvarianter med nedsat udskillelse
Bode et al. New developments in thrombolytic therapy
EP0487660B1 (en) Treatment of thrombotic events
Guerrero et al. Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model
ATE114170T1 (de) Substitutionsvariante des gewebeplasminogenaktivators.
Loscalzo Fibrinolytic therapy
EP0326013A3 (en) Novel proteins derived from human alpha2-plasmin inhibitor or proteins similar thereto
DE69215537D1 (de) t-PA SUBSTITUTIONSVARIANTEN MIT VERBESSERTER FIBRINSPEZIFITÄT
Runge New horizons in the treatment of coronary artery thrombosis
Stewart Interactions of vampire bat plasminogen activator, tissue-type plasminogen activator, and TNK-variants with fibrin, fibrinogen, and the fibrin fragment (DD) E
Nakagaki et al. Inactivation of factor Va by activated protein C on selected human tumor cell lines
Siigur et al. Polypeptides and proteins active in the coagulation process
IE904654A1 (en) "Thrombolytically acting combined preparation"

Legal Events

Date Code Title Description
MK1K Patent expired